Four paraplegic men voluntarily move their legs, an ?unprecedented breakthrough? for paralysis community
Four young men who have been paralysed for years achieved groundbreaking progress
Four young men who have been paralysed for years achieved groundbreaking progress
Nanoparticles have a great deal of potential in medicine: for diagnostics, as a vehicle for active substances or a tool to kill off tumours using heat. ETH Zurich researchers have now developed particles that are relatively easy to produce and have a wide range of applications.
If you put your hand over a switched-on torch in the dark, it appears to glow red. This is because long-wavelength red light beams penetrate human tissue more effectively than short-wavelength blue light. ETH Zurich researchers exploit this fact in a new kind of nanoparticles: so-called plasmonic particles, which heat up when they absorb near-infrared light. This could enable them to kill tumour tissue with heat, for instance.
Gold is a popular material for nanoparticles used therapeutically, as it is well tolerated and does not usually trigger any undesirable reactions. In the characteristic ball or sphere shape of nanoparticles, however, gold does not have the necessary properties to work as a plasmonic particle that absorbs sufficiently in the near-infrared spectrum of light to heat up. To do so, it needs to be moulded into a special shape, such as a rod or shell, so that the gold atoms adopt a configuration that starts absorbing near-infrared light, thereby generating heat. Producing such nanorods or nanoshells in sufficient amounts, however, is complex and expensive.
A team of researchers headed by Sotiris Pratsinis, Professor of Particle Technology at ETH Zurich, has now discovered a trick to manufacture plasmonic gold particles in large amounts. They used their existing know-how on plasmonic nanoparticles and made sphere-shaped gold nanoparticles that display the desired near-infrared plasmonic properties by allowing them to be aggregated. Each particle is coated with a silicon dioxide layer beforehand, which acts as a placeholder between the individual spheres in the aggregate. Through the precisely defined distance between several gold particles, the researchers transform the particles into a configuration that absorbs near-infrared light and thus generates heat.
‘The silicon dioxide shell has another advantage’, explains Georgios Sotiriou, first author on the study and, until recently, a postdoc in Pratsinis
For people whose hands shake uncontrollably due to a medical condition, just eating can be a frustrating and embarrassing ordeal
Christopher Longhurst was part of a team that found a way to pull information from hospital patients’ electronic medical records to reduce the rate of one type of infection.
A computerised safety checklist that automatically pulls information from patients’ electronic medical records was associated with a threefold drop in rates of one serious type of hospital-acquired infection, according to a study by researchers at the Stanford University School of Medicine and Lucile Packard Children’s Hospital Stanford.
The study, conducted in the hospital’s pediatric intensive care unit, targeted bloodstream infections that begin in central lines
A miniaturised dialysis machine has been used to successfully treat a neonate with acute kidney injury, according to an article.
At this time, physicians have to adapt continuous renal replacement therapy (CRRT) machines designed and built for adults to treat babies, but that presents safety and effectiveness challenges for neonates and infants weighing less than 10 kg.
Claudio Ronco, MD, director of the Department of Nephrology, Dialysis, and Transplantation at the International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy, and colleagues designed, developed, and conducted in vitro testing of the miniaturised CRRT machine, aptly named CARPEDIEM (for Cardio-Renal Pediatric Dialysis Emergency Machine), during a 5-year period and began treatment of the first infant on August 29, 2013.
The patient was 72 hours old and in the neonatal intensive care unit with haemorrhagic shock, multiple organ dysfunction, and 63% fluid overload (2.9 kg at birth and 5.2 kg at the start of CRRT). She received more than 400 hours of treatment with the CRRT machine.
The neonatal intensive care unit discharged the patient after 30 days, when she was ‘breathing normally without supplemental oxygen, making adequate amounts of urine, and had normal liver function,’ the clinicians write. The hospital discharged her 20 days later, but she still had clinically significant chronic kidney dysfunction that did not require renal replacement therapy.
In addition to having miniaturised components, CARPEDIEM is capable of fluid control suitable for newborns and infants and can be operated at low flows and pressures and with a fluid balance accuracy. The clinicians chose the name because of its potential for use for multiple indications, including after cardiac surgery with fluid overload and renal impairment, as well as kidney injury from multiple causes.
Four independent operators tested the machine in in vitro laboratory tests before it was approved for human use after 30 months in development, the clinicians write.
In this case, the ability to use a smaller catheter for the low-weight infant precluded use of other available CRRT machines, the authors add.
Although peritoneal dialysis is the predominant treatment mode for neonates, CRRT could improve outcomes in some cases, such as critically ill infants presenting with fluid overload, with sepsis, or after abdominal surgery, the researchers write.
Medscape
People who need multiple surgeries for congenital heart defects undergo procedures that are invasive and challenging partly due to an inability to quickly and safely secure devices inside the heart. Sutures take too much time to stitch and can stress fragile heart tissue, and available clinical adhesives are sub-par.
The creation of a safe and effective adhesive that can be used internally in the body would help these patients, but researchers trying to develop a glue like this have faced hurdles such as ensuring that it is non-toxic and capable of repelling fluids. Now, a study published by Harvard Medical School offers a potential breakthrough.
Scientists at the University of Basel report first ever successful nose reconstruction surgery using cartilage grown in the laboratory. Cartilage cells were extracted from the patient
Investigators at the Cedars-Sinai Regenerative Medicine Institute have discovered eye abnormalities that may help reveal features of early-stage Alzheimer’s disease. Using a novel laboratory rat model of Alzheimer’s disease and high-resolution imaging techniques, researchers correlated variations of the eye structure, to identify initial indicators of the disease.
Alzheimer’s disease is the leading cause of dementia, which is characterised by loss of memory and a progressive decline in cognitive function. To date, more than 26 million people are estimated to suffer from the disease and the number is expected to quadruple by 2050. Despite the disease being described over a century ago, treatment and understanding of the disease remain rather limited.
‘Detecting changes in the brain that indicate Alzheimer’s disease can be an extremely challenging task,’ said Shaomei Wang, MD, PhD, lead author of the study and an associate professor in the Regenerative Medicine Institute and Department of Biomedical Sciences. ‘By using the eye as a window to brain activity and function, we may be able to diagnose patients sooner and give them more time to prepare for the future. Options may include earlier enrolment in clinical trials, developing support networks and dealing with any financial and legal matters.’
Using both animal models and post-mortem human retinas from donors with Alzheimer’s disease, researchers found changes in the retinal pigment epithelial layer, which harbours the supportive cells located in the back of the eye, and in the thickness of the choroidal layer that has blood vessels providing nutrients to the retina. Changes in these two regions were detected using sophisticated, state-of-the-art imaging and immunological techniques.
With high-resolution, microscopic imaging and visual acuity measurements, investigators were able to monitor tissue degeneration in the cell layer and vascular layer at the back of the eye, as well as decline in visual function, that were strongly associated with Alzheimer’s disease.
‘Greater magnitude in these eye abnormalities may mean a greater chance of a patient having Alzheimer’s disease,’ said Alexander Ljubimov, PhD, director of the Eye Program within the Regenerative Medicine Institute and co-author of the study. ‘We found that a rat model showed similar signs to the human ailment in the eye. If true in a larger number of humans, these findings may be used to study Alzheimer’s disease mechanisms and test potential drugs.’
Though additional research is needed to investigate the mechanisms of these ocular changes in relation to changes in the brain, investigators hope to ultimately aid early diagnosis of Alzheimer’s disease by studying the most approachable part of the central nervous system: the eye. Cedars-Sinai has been at the cutting edge of studies on the eye and Alzheimer’s disease with a previous report showing amyloid plaques, a hallmark of Alzheimer’s disease, also build up in the eye using a similar animal model of the disease.
‘It is fascinating that the eye may provide such a window to the brain and eventually predict diseases such as Alzheimer’s, although more human studies are now needed to confirm this animal work,’ said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute and a co-author on the study. Other members of the Regenerative Medicine Institute Eye Program, include Yu Chun Tsai, PhD, a post-doctoral fellow; and Bin Lu, MD, PhD, and Sergey Girman, PhD, both project scientists.
Cedars-Sinai Medical Center
A team of researchers from UCLA and the University of Michigan has developed a material that could help prevent blood clots associated with catheters, heart valves, vascular grafts and other implanted biomedical devices.
Blood clots at or near implanted devices are thought to occur when the flow of nitric oxide, a naturally occurring clot-preventing agent generated in the blood vessels, is cut off. When this occurs, the devices can fail.
Some researchers have sought to solve this problem with implantable devices that gradually release nitric oxide, but their supply of the agent is necessarily limited. Instead, the UCLA
A new feasibility study shows that equipping head and neck cancer patients with home-based sensors to identify potential risks of dehydration during radiation treatment is attainable and acceptable to patients as well as their physicians.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy